Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

indianexpress.com - Sweety Kumari - 'Not a single prescription': How pharma firms are 'moving' codeine cough syrup to Bengal border districts
'Not a single prescription': How pharma firms are 'moving' codeine cough syrup to Bengal border districts
The Indian Express –

Nearly two lakh bottles of codeine-based cough syrup seized in Balurghat have been destroyed, 65 people arrested and 44 cases registered in Dakshin Dinajpur since June. South Dinajpur Superintendent of Police Abhishek Gupta said the scale of sales…

fool.com - Brendan Coffey - Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?
The Motley Fool –

As the global health landscape shifts toward obesity treatments, investors are weighing the rapid growth of Novo Nordisk A/S (NVO +2.41%) against the deep-rooted stability of Pfizer Inc. (PFE +0.21%) to determine the better long-term choice. Novo…

dev.to - Matthew Curtis - 13 of 68 industrial liquidation sales this fall are biotech or pharma equipment.
13 of 68 industrial liquidation sales this fall are biotech or pharma equipment.
DEV Community –

One of the auctions is called 'Pfizer #162'. The auction house labels it Sale #162. It covers bioreactors, chromatography systems and centrifuges at five locations, from Mansfield, Massachusetts to Bothell, Washington, and bidding ends on December…

marketbeat.com - Wall Street Zen Upgrades Avalyn Pharma (NASDAQ:AVLN) to Hold
Wall Street Zen Upgrades Avalyn Pharma (NASDAQ:AVLN) to Hold
MarketBeat –

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) was upgraded by research analysts at Wall Street Zen from a 'sell' rating to a 'hold' rating in a note issued to investors on Saturday, Wall Street Zen reports. AVLN has been the topic of several other…

marketbeat.com - Royalty Pharma (NASDAQ:RPRX) Stock Rating Upgraded by Wall Street Zen
Royalty Pharma (NASDAQ:RPRX) Stock Rating Upgraded by Wall Street Zen
MarketBeat –

Royalty Pharma (NASDAQ:RPRX - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a 'buy' rating to a 'strong-buy' rating in a report issued on Saturday, Wall Street Zen reports. How Royalty Pharma Prints Cash Without…

elizabethnickson.substack.com - elizabeth nickson - Did The Israel and Pharma Lobbies Queer the Trump Presidency?
Did The Israel and Pharma Lobbies Queer the Trump Presidency?
Welcome to Absurdistan –

Calley Means, that slight, dark, fierce intellect who sat at Bobby Kennedy's right hand for the past two years let off a delicious fusillade of shots last week, which wounded then killed off Susie Wiles, Trump's Chief of Staff and her team. It was…

mirror.co.uk - Daniel Bird - Liverpool Hall of Fame statement in full as Ian McNabb's induction axed
Liverpool Hall of Fame statement in full as Ian McNabb's induction axed
Daily Mirror –

Ian McNabb's induction into the Liverpool Legends Hall of Fame has been axed. It comes after the musician, the former frontman of The Icicle Works, defended convicted rapist Russell Brand. The Hall of Fame, established at Liverpool's Beatles…

express.co.uk - Jennie Buzaglo - Music legend's induction into Hall of Fame axed after defending Russell Brand
Music legend's induction into Hall of Fame axed after defending Russell Brand
Daily Express –

Ian McNabb's induction into the Liverpool Legends Hall of Fame has been axed after he made a post defending Russell Brand. McNabb, who found fame fronting Liverpool band The Icicle Works in the 1980s, claimed Brand had been 'stitched up' after he…

seekingalpha.com - Albert Anthony - Principal Financial: Still Bullish After Stellar Q3 Results, With Retirement Niche In Focus
Principal Financial: Still Bullish After Stellar Q3 Results, With Retirement Niche In Focus
Seeking Alpha –

Principal Financial earns a reiterated buy rating, supported by strong market momentum, robust credit ratings, and a diversified, innovative platform. PFG's Q3 results highlight organic growth in retirement and benefits segments, with operating EPS…

fool.com - The Motley Fool Team - Paysign: 3 Key Takeaways for Long-Term Investors
Paysign: 3 Key Takeaways for Long-Term Investors
The Motley Fool –

On its third-quarter 2026 earnings call, held on Nov. 9, 2026, Paysign (PAYS +0.32%) announced a 43% year-over-year revenue increase to $30.8 million, driven by expansion in its pharmaceutical copay assistance business. The shift from transactional…

fool.com - Robert Izquierdo - Better Biotech ETF: First Trust's FBT vs. Invesco's PBE
Better Biotech ETF: First Trust's FBT vs. Invesco's PBE
The Motley Fool –

The First Trust NYSE Arca Biotechnology Index Fund (FBT -0.05%) provides a lower expense ratio and larger assets under management (AUM) compared to the Invesco Biotechnology & Genome ETF (PBE -0.56%), which utilizes a multi-factor quantitative…

indianexpress.com - Ravi Dutta Mishra - How the government's flagship PLI schemes are lagging in job creation
How the government's flagship PLI schemes are lagging in job creation
The Indian Express –

5 min read New Delhi Make us preferred source on Google Your feedback has been reported succesfully. Launched in March 2020, the NDA-government's flagship production-linked incentive scheme (PLI) achieved 76% of its investment target and 64% of its…

straitstimes.com - Rei Kurohi - ST×NLB Cross-References: Former Capitol haunt named after a milk brand
ST×NLB Cross-References: Former Capitol haunt named after a milk brand
The Straits Times –

SINGAPORE – This week's ST×NLB Crossword was co-constructed by NLB's John Choo and Sasha Tan, who are part of a team of 40 volunteers from both organisations. Our title clue for this week references the MAGNOLIA (18D) Snack Bar, the…

fool.com - Adria Cimino - Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?
Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?
The Motley Fool –

Commercial-stage biotech companies make great investments for those of us looking for both safety and growth. Their portfolios of commercialized products offer a certain degree of revenue stability since patients always need their medicines…

fool.com - Keith Speights - Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?
Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?
The Motley Fool –

Pfizer (PFE +0.21%) and AbbVie (ABBV +0.20%) rank among the biggest drugmakers in the world. Both pharma stocks have also been favorites for many income investors through the years. However, Pfizer and AbbVie offer distinctly different attractions…

Receive a Daily briefing on Pharma Industry News

Get Started